[1] Stewart B.W., Kleihues P., World Cancer Report. 11-21. International Agency For Research On Cancer Publications, 2003.
[2] Wilkins, M. R., Sanchez, J. C., Gooley, A. A., Appel, R. D., Humphery-Smith, I., Hochstrasser, D. F., ve Williams, K. L. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnology and genetic engineering reviews, 13(1): 19-50, 1996.
[3] Alacalı, M., Mide kanseri, mide kanseri taramaları ve mide kanserinden korunma.
Ankara Medical Journal, 12(4): 195-198, 2012.
[4] Hanahan, D., and Weinberg, R. A., The hallmarks of cancer.cell, 100(1): 57-70, 2000.
[5] Vardar, A., Kanserin Tanımı, Belirtileri ve Çeşitleri. Avrasya Hospital Sağlık Dergisi Kanser Özel Sayısı, 53: 34-35, 2015.
[6] Ogden, J., Health psychology. McGraw-Hill Education (UK). 2012.
[7] P. Boyle, and B. Levin (Eds.). Dünya kanser raporu 2008. Uluslararası Kanser Araştırma Kurumu. 2008.
[8] Tuncer, M., T.C. Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı Ulusal Kanser Programı. 2009.
[9] Edmondson, R. J., Monaghan, J. M. , The epidemiology of ovarian cancer, Int. J.
Gynecol. Cancer, 11: 423-429, 2001.
45
[10] Chu, C.S., Rubin, S.C., Screening for ovarian cancer in the general population, Best Practice & Research Clinical Obstetrics and Gynaecology, 20(2): 307-320, 2005.
[11] Allain, D.C., Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology, J. Mol. Diagn, 10(5): 383–395,2008.
[12] American Cancer Society, Ovarian Cancer, Global Cancer Fact & Figures American Cancer Society, Atlanta, GA, USA. 2011.
[13] Dina, R.and, G. Rustin, Carcinoma of the ovaries and fallopian tubes’ in Shaw, Soutter WP, Stanton SL (eds) Gynaecology, London: Churchill Livingstone. 2002.
[14] Berek, J.S., Novak Jinekoloji. Erk A (Ed). Over Kanseri’nde. İstanbul: Nobel Tıp Kitabevi. 1245-321, 2004.
[15] Köse, M. The Ministry of Health of Turkey Health Statistics Yearbook 2015.
Edited by Berrak Basara, Cemil Guler, and Gokalp Yentur. Ankara: Ministry of Health. 2016.
[16] Roett, M.A., Evans, P., Ovarian cancer: an overview, Am Fam Physician, 80(6):
609-616, 2009.
[17] Pearce, C.L., Templeman, C., Rossing, M.A., Lee, A., Near, A.M., ve diğ, Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies, Lancet Oncol., 13(4): 385– 394, 2012.
46
[18] Siegel R.L.; Kimberly D. Miller; Ahmedin Jemal. Cancer Statistics, Ca Cancer J Clin, 65: 5–29, 2015.
[19] Kindelberger, D.W., Lee, Y., Miron A ve diğ, Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg.
Pathol. 31(2): 161–169, 2007.
[20] Kopuz, E., Saip, E., Salihoglu, Y., Jinekolojik tümörler, Klinik Onkoloji. 2000:
289-290.
[21] Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. WHO 4(6): 307-316. 2014
[22] Danijela Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61(3): 183-203, 2011.
[23] Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Robert L et al.
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. 118(12): 3087-3094, 2012.
[24] Hong MK, Chu TY, Ding DC. The fallopian tube is the culprit and an accomplice in type II ovarian cancer: A review. TZU CHİ medical. 25(4): 203-205, 2013.
[25] Kadar N., Krumerman M., possible metaplastic origin ofllymph node metastases in serous ovarian tumor of low malignant potential (borderline serous tumor).
Gynecol Oncol 59: 394-397, 1995.
[26] Tavassoli FA., Devilee P. WHO Histological Classification of Tumours of the ovary. Pathology and genetics of tumours of the breast and female genital organs.
113-145, 2003.
47
[27] Türk Patoloji Derneği Meslek İçi Eğitim Kursları 2002 Over Tümörleri Z Calay, Ş ilvan, A İplikçi, S Tuzlalı, E Yavuz 1-19.
[28] Kumar V., Abbas A.K., Fausto N; The femalle genital tract, Chapter 22, in Robbins and Cotran Pathologic Basis of Disease,Elsevier Saunder, Philladellphia, 7:
1059-1118, 2005.
[29] Rosai J, Female reproductive system, Chapter 19, in Rosai and Ackerman’s Surgical Pathology, 2(9): 1659–1681, 2004.
[30] Berek, J.S., Crum, C., Friedlander, M., Cancer of the ovary, fallopian tube, and peritoneum. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 119(2): 118-129, 2012.
[31] Anonim, Society of Gynecologic oncology, https://www.sgo.org/clinical-practice/guidelines/new-figo-ovarian-cancer-staging-guidelines (Erişim tarihi:
17.01.2019)
[32] Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary. J Gynecol Oncol 26(2): 87-89, 2015.
[33] Clark TG, Stewart ME, Altman DG. A prognostic model for ovarian cancer. Br J Cancer 85: 944-52, 2001.
[34] Cragun, J.M., Screening for ovarian cancer, Cancer Control. 18(1): 16-21, 2011.
[35] Nyugen, L., Cardenas-Goicoechea, S.J., Gordon, P., Curtin, C., Momeni, M., Chuang, L., Fishman, D., Biomarkers for early detection of ovarian cancer, Women’s Health, 9(2): 171-187, 2013.
[36] Myers, E.R., Bastian, L.A., Havrilesky, L, ve diğ, Management of adnexal mass.
Evid. Rep. Technol. Assess. 130, 1-145, 2006.
48
[37] Granberg, S., Wikland, M., Jansson, I., Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation, Gynecol Oncol. 35(2): 139–144,1989.
[38] Lewis, S., Menon, U., Screening for ovarian cancer, Reviews in Gynaecological Practice. 4: 156–161, 2004.
[39] Fishman, D.A., Cohen, L., Blank, S.V., ve diğ, The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer, Am. J. Obstet. Gynecol.
192(4): 1214–1221,2005.
[40] Cohen, L.S., Escobar, P.F., Scharm, C., Glimco, B., Fishman, D.A., Threedimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction, Gynecol Oncol. 82(1): 40–48, 2001.
[41] Kurjak, A., Kupesic, S., Sparac, V., Kosuta, D., Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions, Ultrasound Obstet Gynecol, 16(4): 365–71, 2000.
[42] American College of Obstetricians and Gynecologists. Prolog Gynecology and Surgery. American College of Obstetricians and Gynecologists, Washington, DC, USA.2009.
[43] D Pessayre., Cytocroms P450 s in formain of metabolic reactives Terapie, 48:
537-542, 1993.
[44] N Vural., Toksik maddelerin metabolizması. Toksikoloji, Ankara Üniv.
Yayınevi 73: 43-45, 2005.
[45] PJ Donald., Marisuana smoking-possible cause of head and neck carcinoma in young patients.Otolaryngol Head Neck Surg, 94: 517, 1986.
49
[46] FP Guengerich. Characterization of human microzomal P450 enzyms. Ann.
Rev. Pharmacol.Toxicol, 29: 241-246, 1989.
[47] J Caldwell. Conjuction reactions in foreing compound metabolism:defenitanion, consequens and specific variation. Drug Metab.Rev. 13: 745-777, 1982.
[48] Cengiz, M., Hacihanefioglu, S., & Cenani, A. Glutathione and related enzymes in rat liver treated with methyl nitrosourea. Journal of basic and clinical physiology and pharmacology, 7(4): 341-346, 1996.
[49] Boar, P., Coggan, M., Johnston, P., Ross, V., Suzuki, T., & Webb, G. Genetic heterogeneity of the human glutathione transfereses: A complex of gene families.
Pharmacology & therapeutics. 48(3): 357-369, 1990.
[50] Halliwell, B. Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutrition reviews. 57(4): 104-113, 1999.
[51] Hayes, J. D., & Pulford, D. J. The glutathione S-transferase supergene family:
regulation of GST and the contribution of the lsoenzymes to cancer chemoprotection and drug resistance part II. Critical reviews in biochemistry and molecular biology.
30(6): 521-600, 1995.
[52] Commandeur J.N.M, Stijntjes G.J, Vermeulen N.P.E. Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Phar Rev. 47: 271-330, 1995.
[53] Whalen R, Boyer T.D. Human Glutathione-S-Transferases. Sem Liver Dis.
18(4): 345-58, 1998.
[54] Mannervik, B., & Widersten, M. Human glutathione transferases: classification, tissue distribution, structure, and functional properties. Advances in drug metabolism
50
in man; Pacifici, G.M., Frachia, G.N., Eds.; European Commission: Lüxembourg, 407-459, 1995.
[55] Board, P. G. Biochemical genetics of glutathione-S-transferase in man.
American journal of human genetics. 33(1): 36-43, 1981.
[56] Hayes, J. D., & Strange, R. C. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 61(3): 154-166, 2000.
[57] Di Pietro, G., Magno, L. A. V., & Rios-Santos, F. Glutathione S-transferases: an overview in cancer research. Expert opinion on drug metabolism & toxicology, 6(2):
153-170, 2010.
[58] Takahashi, Y., Campbell, E. A., Hirata, Y., Takayama, T., & Listowsky, I. A basis for differentiating among the multiple human Mu-glutathione S-transferases and molecular cloning of brain GSTM5. Journal of Biological Chemistry, 268(12):
8893-8898, 1993.
[59] Strange, R. C., Spiteri, M. A., Ramachandran, S., & Fryer, A. A. Glutathione-S-transferase family of enzymes. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 482(1): 21-26, 2001.
[60] Meyer D. J., Coles B., Pemble S. E., Gilmore, K. S., Fraser, G. M., & Ketterer B. Theta, a new class of glutathione transferases purified from rat and man.
Biochemical Journal. 274(2): 409-414, 1991.
[61] Ginsberg, G., Smolenski, S., Hattis, D., Guyton, K. Z., Johns, D. O., &
Sonawane, B. Genetic polymorphism in glutathione transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity. Journal of Toxicology and Environmental Health, Part B. 12(5-6): 389-439, 2009.
51
[62] Coggan M., Whitbread A., Whittington A., Board P., Structure and organization of the human theta-class glutathione s-transferase and D-dopachrom tautomerase gene complex. Biochemical Journal. 334: 617-623, 1998.
[63] Mainwaring, G. W., Williams, S. M., Foster, J. R., Tugwood, J., & Green, T.
The distribution of theta-class glutathione S-transferases in the liver and lung of mouse, rat and human. Biochemical Journal. 318(1): 297-303, 1996.
[64] JA Mascow, AJ Towvsed, ME Goldsmith, et al. Isolation of the human anionic glutathione transferase cDNA and reletion of its gene expressione to estrogen receptor content in primary breast cancer. Proc Natl Acad SCİ USA. 85: 6518-6522, 1988.
[65] B Mannevrik. The isozyme of glutathione transferase. Avdan Enzymol. 57: 357-417, 1985.
[66] JD Hayes, TJ Mantle. Use of immünoblot techniques to discriminate between the glutathine transferase Yf, Yk, Yn/Yb, and Yc subunıts and to study their extra hepatic distribution. Biochemical Journal. 233: 779-778, 1986.
[67] J.A. Moscow, C.R. Fairchld, M.J.Madden, D.T.Ransom, H.S.Wieand ve diğ, Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 49: 1422-8, 1989.
[68] RS Cotran, V Kumor, T Collins: Robbins Pathologic basis of disease, 6th
Edition, W. B. Saunders Coy, Philadelphia. 6: 276-302, 1999.
[69] AJ., Levine, J Momand, CA Finlay: The p53 tumour supressor gene, xlature 351: 453-456, 1991.
[70] LJ .Ko, C Prives, P53: puzzle and paradigm.Genes Dev.10: 1054-1072, 1996.
52
[71] AJ Levine: p53, the celluler gatekeeper for growth and division.Cell 88:323-331, 1997.
[72] C.Prives and PA Hall: The p53 pathway, J Pathol 187: 112-126, 1999.
[73] K Somasundaram, Front Biosci: Tumor supressor p53: regulation and function.5: 424-437, 2000.
[74] DP Lane, Benchimol S:P53: Oncogene or anti oncogene Genes Dev. 4(1): 1-8, 1990.
[75] A Maity, WG Mckenna, Muschel Rj. The molecular basis for cll cycle delays following ionizing radiation: A review. Radiother Oncol 31: 1-13, 1994.
[76] J. R. Marks, A. M. Davidoff, B. J. Kerns, P. A. Humphrey, J. C. Pence, R. K.
Dodge, D. L. Clarke-Pearson, J. D. Iglehart, R. C. Bast, Jr., And A. Berchuck, Ovarian Expression And Mutation of p53 İn Epithelial Ovarian Cancer.Cancer Research 51: 2979-2984, 1991.
[77] J.A. Green, L.J. Robertson & A.H. Clark Clatterbridge Centre for Oncology, Merseyside L63 4JY;Glutathione-S-Transferase expression in benign and malignant ovarian tumors. Br. J. Cancer 68: 235-239, 1993.
[78] J. Kupryjańczyk, A D Thor, R Beauchamp, V Merritt, S M Edgerton, D A Bell, and D W Yandell. P53 gene mutations and protein accumullation in human ovarian cancer. 90(11): 4961-4965, 1993.
[79] J.Jonathan,O. Herod, Aristides, Eliopoulos, Jane Warwick, Gerald Niedobitek, Lawrence S. Young and David J. Kerr.The Prognostic Signifiance of Bcl-2 and p53 Expression İn Ovarian Carcinoma. Cancer Research 56: 2178-2184, 1996.
53
[80] S.W. Baxter, E.J. Thomas and I.G. Campbell. GSTM1 null polimorphism and susceptibility to endometriosis and ovarian cancer.Carcinogenesis, 22(1): 63-65, 2001.
[81] S. Oğuztüzün, M. Kılıç, N.Tandoğan, L. Öztürk. Usefulness of CA 15-3 for breast or ovarian primary sites in metastatic adenocarcinoma of pleural fluid. Türk J Biol 36: 171-175, 2012.
[82] Strange RC, Fryer AA. The Glutathione S Tranferases: in fluence of polimorphism on cancer susceptibillity. IARC Sci Publ. 148: 231-49, 1999.
[83] Fariba Abbasi, Arefeh Esmaili, Zahra Yekta, Abbas Saffarifard.Expression of p53 in ovarian epithelial tümörs and ıts correlation with histopatological parameters.
28(1): 3-6, 2016.
[84] Karen S. Anderson, Jessica Wong, Allison Vitonis, Christopher P. Crum, Patrick M. Sluss, Joshua LaBaer and Daniel Cramer. Serous Patentials İn Ovarian Cancer and p53 Autoantibodies As Prognostic Biomarkers İn Serous Ovarian Cancer. Cancer Epidemiology And Prevention Biomarkers.19(3): 859-868, 2010.
[85] Toyomi Satoh Masato Nishida HajimeTsunoda Takeshi Kubo.Expression of glutathione-s-transferase GSTP1 in human malignant ovarian tümors European Journal of Obstetrics & Gynecology and Reproductive Biology 96: 202-208, 2001.